Trial Profile
AGN 201904 [AGN-201904Z] versus esomeprazole in the prevention of aspirin-induced stomach or upper intestinal damage in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2011
Price :
$35
*
At a glance
- Drugs AGN 201904Z (Primary) ; Esomeprazole
- Indications NSAID-induced gastrointestinal damage
- Focus Therapeutic Use
- Sponsors Allergan
- 01 Jun 2011 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 22 Mar 2008 New trial record.